The University of Chicago Header Logo

Connection

Clarissa Parker to Antineoplastic Agents

This is a "connection" page, showing publications Clarissa Parker has written about Antineoplastic Agents.
Connection Strength

0.315
  1. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014 Mar 30; 5(6):1392-433.
    View in: PubMed
    Score: 0.102
  2. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs. 2006 Jul; 17(6):697-704.
    View in: PubMed
    Score: 0.060
  3. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 2006 Sep; 53(3):331-7.
    View in: PubMed
    Score: 0.060
  4. Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hematol Oncol. 2003 Jan; 1(1):33-8.
    View in: PubMed
    Score: 0.047
  5. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010 Jan 06; 102(1):47-53.
    View in: PubMed
    Score: 0.038
  6. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007 Sep; 2(9):845-53.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.